Published in Food and Drug Law Weekly, July 30th, 2004
Adolor is seeking marketing approval of Entereg for the management of postoperative ileus (POI) by accelerating time to recovery of gastrointestinal (G.I.) function following abdominal or pelvic surgeries. POI is a temporary impairment of G.I. function that can occur following many types of surgery. GlaxoSmithKline and Adolor are collaborating on the worldwide development and commercialization of Entereg.
"One of our key targets for 2004 was to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.